Compare Enveric Biosciences Inc (ENVB) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs QUALCOMM, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while QUALCOMM, Inc. trades at $174.18 (market cap $187.95B). The key difference: QUALCOMM, Inc. is far larger — about 27639.7× Enveric Biosciences Inc's market cap, and QUALCOMM, Inc. pays a 2.09% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and QUALCOMM, Inc. for 87 Days on average.
| ENVB | QCOM | |
|---|---|---|
Market Cap | $6.80M | $187.95B |
Volume | 64,867 | 9,535,042 |
Sector | Health | Technology |
52-Week High | $10.80 | $251.10 |
52-Week Low | $1.27 | $124.07 |
Typical Hold Time | 14 Days | 87 Days |
Enterprise Value | -$1.49M | $194.92B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Qualcomm (QCOM) trades at $177.06, down 2.21% today, with a bearish technical signal and support near $175. The company reported strong revenue of $44.28B in 2025 but net income fell to $5.54B, reflecting margin pressure. Recent news highlights a strategic AI partnership with Amazon, potentially opening a $60B opportunity, while analyst consensus remains mixed with a $204.48 price target.
QCOM's outlook is balanced by AI growth potential against near-term headwinds. The Amazon deal and diversification into automotive and data centers offer upside, but execution risks, competition, and dependence on smartphone markets pose challenges. Valuation metrics like a P/E of 20.12 appear reasonable if AI initiatives accelerate revenue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
